Latest Ratios: P/E Ratio -11.0x · EV/EBITDA N/A · ROE -68.5%. (2013–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $296M | $337M | $80M | $24M | $51M | $62M | $88M | $51M | $33M | $58M | $46M |
| Enterprise Value | $207M | $248M | $43M | $15M | $40M | $50M | $83M | $57M | $47M | $66M | $6M |
| P/E Ratio → | -10.96 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 78.37 | — | 25.23 | 15.56 | 13.67 | 18.63 | 2.65 | 200.19 | 72.72 |
| P/B Ratio | 4.59 | 5.23 | 5.57 | — | 8.72 | 4.10 | 23.12 | — | — | — | 1.46 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 42.40 | — | 19.58 | 12.45 | 12.92 | 20.56 | 3.78 | 227.10 | 8.92 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | — | 100.0% | 100.0% | -71.7% | -447.0% | -85.3% | -13522.0% | -7115.8% |
| Operating Margin | — | — | -2377.6% | — | -1116.9% | -540.9% | -184.8% | -755.9% | -159.4% | -17416.5% | -8678.2% |
| Net Profit Margin | — | — | -1815.3% | — | -949.7% | -324.3% | -132.5% | -793.7% | -63.6% | -5547.8% | -2579.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -68.5% | -68.5% | -129.1% | — | -182.0% | -136.6% | -224.1% | — | — | -269.9% | -28.4% |
| ROA | -42.1% | -42.1% | -74.9% | -91.5% | -65.3% | -64.5% | -70.7% | -246.1% | -43.4% | -39.2% | -22.4% |
| ROIC | — | — | — | — | — | -1911.4% | — | — | — | — | — |
| ROCE | -56.4% | -56.4% | -144.5% | -196.7% | -106.1% | -170.7% | -553.3% | — | — | -230.1% | -86.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.01 | — | 0.12 | 0.06 | 0.24 | — | — | — | 0.35 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.38 | -2.56 | — | -1.95 | -0.82 | -1.27 | — | — | — | -1.28 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -5179.00 | -5179.00 | — | -1996.38 | -1657.20 | -1467.00 | -17.50 | -10.95 | -6.19 | -16.41 | -138.08 |
Net cash position: cash ($89M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.54 | 13.54 | 7.34 | 1.00 | 3.52 | 1.84 | 1.13 | 0.21 | 0.18 | 0.76 | 4.56 |
| Quick Ratio | 13.54 | 13.54 | 7.34 | 1.00 | 3.52 | 1.83 | 1.07 | 0.21 | 0.18 | 0.75 | 4.56 |
| Cash Ratio | 13.39 | 13.39 | 7.07 | 0.89 | 1.57 | 1.58 | 0.90 | 0.13 | 0.09 | 0.44 | 4.50 |
| Asset Turnover | — | — | 0.03 | — | 0.06 | 0.16 | 0.43 | 0.30 | 1.45 | 0.01 | 0.01 |
| Inventory Turnover | — | — | — | — | — | — | 29.69 | — | — | 244.69 | — |
| Days Sales Outstanding | — | — | 22.25 | — | 2245.71 | 5.19 | 8.99 | 0.66 | — | 10034.36 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.5% | 2.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.5% | 2.0% |
| Shares Outstanding | — | $8M | $6M | $2M | $2M | $2M | $1M | $757301 | $311231 | $242331 | $238638 |
Clinical trial funding dependency
Based on reported figures, VTVT trades at a price-to-book ratio of 4.59, which suggests that the market is pricing the equity based on the potential of its pipeline assets rather than current earnings, as evidenced by the negative TTM P/E of -10.96 observed in recent filings.
The valuation reflects a significant discount compared to peers who have successfully navigated late-stage clinical hurdles, likely due to the market's skepticism regarding the company's historical trial failures. Investors should monitor whether the current P/B multiple remains supported by the majority shareholder's backing or if it contracts as the cash runway shortens.
As reported in financial statements, VTVT's profitability remains fundamentally negative, with the 2026Q1 net margin of 65.5% serving as a non-recurring outlier driven by milestone payments rather than a sustainable improvement in the company's underlying operational earning power or core business model efficiency.
The absence of consistent gross margins highlights the company's status as a pre-revenue clinical entity. Analysts should disregard the anomalous quarterly profitability and focus on the persistent operating losses, which indicate that the company remains entirely dependent on external capital to fund its ongoing R&D activities.
According to recent SEC filings, VTVT maintains a current ratio of 14.36 as of 2026Q1, which provides a substantial liquidity cushion compared to the 1.00 ratio seen in 2023Q4, effectively mitigating the immediate risk of insolvency while the company advances its TTP399 clinical program.
While the current ratio appears robust, it is highly sensitive to the timing of capital raises and clinical trial expenditures. The company's liquidity position is adequate for the near term, but investors should remain cautious as this metric will likely deteriorate rapidly if the Phase 3 trial enrollment extends beyond current projections.
As disclosed in financial statements, the use of P/E ratios to evaluate VTVT is fundamentally flawed, as the company's sporadic milestone-based revenue creates extreme volatility in net income that obscures the true economic reality of its cash-burning, R&D-intensive clinical development business model.
Investors should instead focus on the 'cash runway to catalyst' ratio, which provides a more accurate assessment of the company's ability to reach critical clinical milestones without requiring dilutive financing. Relying on traditional earnings multiples in this context may lead to a significant mispricing of the company's intrinsic value.
Includes 30+ ratios · 13 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VTVT stock.
vTv Therapeutics Inc.'s current P/E ratio is -11.0x. This places it at the 50th percentile of its historical range.
vTv Therapeutics Inc.'s return on equity (ROE) is -68.5%. The historical average is -133.9%.
Based on historical data, vTv Therapeutics Inc. is trading at a P/E of -11.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.